Trial Profile
Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Isotretinoin (Primary) ; Lorukafusp alfa (Primary) ; Sargramostim (Primary) ; Sargramostim (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 29 Jul 2019 Results assessing anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastomapublished in the Clinical Cancer Research
- 11 May 2016 Status changed from active, no longer recruiting to completed.
- 11 Jun 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.